Therefore, the main reason for choosing the PRDM5-NDNF pair was because of the potential role of PRDM5 as an oncogene in MM and the fact that NDNF expression was highly correlated with that of PRDM5. These two coexpressed genes reside in a 500-kb region showing clear de novo activation in MM (Fig. 4A,B), and such coexpression was validated in an additional sample cohort of 10 MM patients and 10 MM cell lines by RT-qPCR (Supplemental Fig. S16A). This evidence concerns the gene PRDM5 and Miyoshi myopathy.